<DOC>
	<DOCNO>NCT01638442</DOCNO>
	<brief_summary>The objective study evaluate safety tolerability ; determine effect food pharmacokinetics ( PK ) CHR-2797 normal healthy male subject .</brief_summary>
	<brief_title>Crossover Trial Effect High-Fat Meal PK Oral CHR 2797 Healthy Male Subjects</brief_title>
	<detailed_description>This single center , open-label , 2-arm , 2-way , crossover trial ass effect food CHR-2797 PK follow single 120 mg dose . Approximately 18 normal , healthy male subject enrol least 12 subject complete study . Two 60 mg capsule administer 120 mg dose CHR-2797 Days 1 8 high-fat meal fast state accord randomization schedule . Subjects confine clinical research unit ( CRU ) time Period 1 Check-in Clinic Discharge Day 3 , return CRU Day 7 Period 2 Check-in remain CRU Study Completion ( Day 10 Period 2 ) . Blood sample PK analysis collect 48 hour post dose .</detailed_description>
	<mesh_term>Glycine</mesh_term>
	<criteria>1 . Male subject 18 55 year age , inclusive . 2 . Within BMI range 18.5 29.9 kg/m2 , inclusive . 3 . In good health , determine clinically significant ongoing disease condition require medication , and/or finding medical history , physical examination , 12lead ECG , vital sign . 4 . Clinical laboratory evaluation ( include chemistry panel fast [ fast approximately 10 hour ] , CBC , UA ) within reference range test laboratory , unless deem clinically significant Investigator . 5 . Negative test select drug abuse Screening ( include alcohol ) Checkin ( include alcohol ; Appendix A ) . 6 . Negative hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] hepatitis C virus [ antiHCV ] , negative HIV antibody screen ( Appendix A ) ; 7 . Males either sterile agree use 1 follow approve method contraception : male condom spermicide ; sterile sexual partner ; use female sexual partner intrauterine device spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ( e.g. , NuvaRingÂ® ) , diaphragm spermicide ; cervical cap spermicide ; oral , implantable , transdermal , injectable contraceptive Checkin ( Day 1 Period 1 ) 90 day follow Clinic Discharge ( Day 10 ) . 8 . Able comprehend willing sign Informed Consent Form ( ICF ) . 1 . Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder ( determined Investigator ) . 2 . Have disease condition require daily medication . 3 . History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator . 4 . History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug ( except appendectomy , hernia repair , and/or cholecystectomy allow ) . 5 . History presence abnormal ECG , , Investigator 's opinion , clinically significant . 6 . History alcoholism drug addiction within 1 year prior Checkin ( Day 1 Period 1 ) . 7 . Use tobacco nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) within 6 month prior Checkin ( Day 1 Period 1 ) . 8 . Participation investigational study drug trial receipt investigational study drug occur within 30 day prior Checkin ( Day 1 Period 1 ) . 9 . Use prescription medications/products within 14 day prior Checkin ( Day 1 Period 1 ) , unless deem acceptable Investigator ; 10 . Use overthecounter ( OTC ) , nonprescription preparation ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ) within 7 day prior Checkin ( Day 1 Period 1 ) , unless deem acceptable Investigator . 11 . Use alcohol , grapefruit , caffeinecontaining food beverage within 72 hour prior Checkin ( Day 1 Period 1 ) , unless deem acceptable Investigator . 12 . Poor peripheral venous access . 13 . Donation blood 30 day prior Screening Study Completion , inclusive , plasma 2 week prior Screening Study Completion , inclusive . 14 . Receipt blood product within 2 month prior Checkin ( Day 1 Period 1 ) . 15 . Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Male subject , healthy</keyword>
</DOC>